CODEXIS INC (31)

Browse by Contract Category

Contracts

Enzyme Supply Agreement by and between the Company and Pfizer Ireland Pharmaceuticals (Filed With SEC on November 4, 2022)
Change in Control Severance Agreement by and between the Company and Kevin Norrett dated September 12, 2022 (Filed With SEC on November 4, 2022)
Offer Letter by and between the Company and Kevin Norrett (Filed With SEC on November 4, 2022)
Ninth Amendment to Loan and Security Agreement, effective as of September 30, 2021, by and between Codexis, Inc. and Western Alliance Bank (Filed With SEC on November 5, 2021)
Lease Agreement by and between the Company and ARE-San Francisco No. 63, LLC. dated as of (Filed With SEC on May 7, 2021)
Platform Technology Transfer and License Agreement, dated May 2, 2019, by and between the Company and Novartis Pharma AG (Filed With SEC on August 6, 2019)
Employment Agreement by and between the Company and Stephen Dilly (Filed With SEC on November 4, 2022)
Transition and Separation Agreement by and between (Filed With SEC on November 4, 2022)
Description of Codexis' Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 28, 2022)
Amendment No. 5 to Sitagliptin Supply Agreement, effective as of July 1, 2021, by and between Codexis, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on November 5, 2021)
Equity Distribution Agreement, dated as of May 7, 2021, between Codexis, Inc. and Piper Sandler & Co (Filed With SEC on May 7, 2021)
Underwriting Agreement, dated as of December 2, 2020, among Codexis, Inc. and Jefferies LLC, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, as... (Filed With SEC on December 7, 2020)
Eighth Amendment to Loan and Security Agreement by and between the Company and Western Alliance Bank dated as of September 30, 2020 to Loan and Security (Filed With SEC on November 6, 2020)
Letter Agreement, effective as of February 21, 2020, by and between Codexis, Inc. and GlaxoSmithKline Intellectual Property Development Limited (Filed With SEC on May 8, 2020)
Strategic Collaboration and License Agreement, effective as of March 23,202, by and between Codexis, Inc. and Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of... (Filed With SEC on May 8, 2020)
Description of the Common Stock of Codexis, In (Filed With SEC on February 28, 2020)
Seventh Amendment to Loan and Security Agreement by and between the Company and Western Alliance Bank dated as of September 30, 2019 (Filed With SEC on November 6, 2019)
Sixth Amendment to Loan and Security Agreement by and between the Company and Western Alliance Bank dated as of July 11, 2019 (Filed With SEC on November 6, 2019)
Amendment to Employment Agreement between the Company and John Nicols, effective as of June 28, 2019 (Filed With SEC on November 6, 2019)
Employment Agreement by and between the Company and Ross Taylor effective as of August 4, 2019 (Filed With SEC on November 6, 2019)
Form of Amended and Restated Change in Control Severance Agreement between the Company and certain of its officers (Filed With SEC on November 6, 2019)
Registration Rights Agreement, dated as of June 20, 2019, by and between Codexis, Inc. and Casdin Partners Master Fund, L.P (Filed With SEC on June 20, 2019)
Securities Purchase Agreement, dated as of June 20, 2019, by and between Codexis, Inc. and Casdin Partners Master Fund, L.P (Filed With SEC on June 20, 2019)
Codexis, Inc. 2019 Incentive Award Plan (Filed With SEC on June 12, 2019)
Eighth Amendment to Lease, effective as of February 8, 2019, by and between the Company and Metropolitan Life Insurance Company (Filed With SEC on May 8, 2019)
Fifth Amendment to Loan and Security Agreement effective as of January 23, 2019 by and between the Company and Western Alliance Bank (Filed With SEC on May 8, 2019)
Amendment No. 2 to Platform Technology Transfer and License Agreement by and between Merck and the Company dated as of January 1, 2019 (Filed With SEC on May 8, 2019)
Letter Agreement to Global Development, Option and License Agreement by and among the Company, Nestec Ltd. and Nestle Health Science S.A., effective as of December 12, 2018 (Filed With SEC on March 1, 2019)
Separation Agreement by and between Michael Aldridge and the Company, dated August 17, 2018 (Filed With SEC on March 1, 2019)
Amendment No. 1 to Platform Technology Transfer and License Agreement by and between the Company and Merck Sharp & Dohme Corp., dated as of October 10, 2018 (Filed With SEC on March 1, 2019)
Amendment No. 1 to Global Development, Option and License Agreement by and among the Company, Nestec Ltd. and Nestl Health Science S.A., effective as of July 26, 2018 (Filed With SEC on March 1, 2019)